Kos Pharmaceuticals, Inc (KOSP) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Kos Pharmaceuticals, Inc (KOSP)

An SI Board Since March 1997

Posts	SubjectMarks	Bans	Symbol
118	20	0	KOSP

Emcee: DD™	Type: Unmoderated

Introduction Market Data Compact

Kos Pharmaceuticals, Inc went public today @$20 1/4 per share, closing up 1 3/4.

Description:

Kos Pharmaceuticals develops pharmaceuticals to treat chronic cardiovascular and respiratory diseases. The company's cardiovascular products are primarily controlled-release, once-a-day, oral dosage formulations, while its respiratory products are aerosolized inhalation products. The company has developed Niaspan, an oral drug
composed of niacin, for the treatment of multiple lipid disorders which are associated with coronary heart disease. Kos has agreements with Fuisz Technologies for the development of products using a technology developed by Fuisz. The company also sponsors basic research at Tufts University and Boston University.

Any/all constructive commentary is appreciated.

DD

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
118	Abbott to Expand Presence in Lipid Management Market With Acquisition of Kos Pha	kenhott	-	11/6/2006
117	gs: Kos Pharmaceuticals, Inc. (KOSP): Raising EPS on better pricing, softer volu	mopgcw	-	8/11/2006
116	Skyepharma, Kos agree marketing, distribution deal for Flutiform in US LONDON (	nigel bates	-	5/8/2006
115	This first came out on Friday, missed it then. From Merrill: Estimate Change; “	tom pope	-	12/19/2005
114	Invitation for a KOSP aficionado: finance.messages.yahoo.com T.i.a. Dew	DewDiligence_on_SI	-	9/11/2005
113	NYT. Mention of KOSP and niacin. --------------------------------------------	tom pope	-	6/28/2005
112	Merrill: Kos Pharmaceuticals Inc Company Update; Raising Price Target to $75	tom pope	-	6/22/2005
111	I learned something here. My knee jerk reaction when I read the initial announc	kenhott	-	5/5/2005
110	Merrill: Price Objective Changes Kos Pharmaceuticals Inc (KOSP, $54.29, C-1-9)	tom pope	-	5/5/2005
109	>>WOODCLIFF LAKE, N.J., April 27 /PRNewswire-FirstCall/ -- Barr Pharmaceut	tuck	-	4/27/2005
108	It all depends on the terms of the deal and whether it gets approved by the FTC.	IRWIN JAMES FRANKEL	-	3/30/2005
107	I have sold this morning after buying a couple of weeks ago. Not sure why such	kenhott	-	3/30/2005
106	Barr, Kos in talks over cholesterol drug patent <i> KOSP up about $6</	Doc Bones	-	3/30/2005
105	gs: Kos Pharmaceuticals, Inc. EPS (FY Dec) 2004E $1.94, 2005E $2.33 In-Line/Neut	mopgcw	-	12/9/2004
104	GS: Kos Pharmaceuticals, Inc. EPS (FY Dec) 2004E $1.67, 2005E $2.32 In-Line/Neut	mopgcw	-	11/11/2004
103	Yup. (eom)	scaram(o)uche	-	11/4/2004
102	There are some of us reading and appreciating all info posted here. thanks stev	sjemmeri	-	11/4/2004
101	URL for the earnings release. Apparently SI won't accept the misspellings i	Lance Bredvold	-	11/4/2004
100	GS: Kos Pharmaceuticals, Inc. EPS (FY Dec) 2004E $1.67, 2005E $2.32 In-Line/Neut	mopgcw	-	10/31/2004
99	GS: Kos Pharmaceuticals, Inc. EPS (FY Dec) 2004E $1.69, 2005E $2.32 In-Line/Neut	mopgcw	-	9/27/2004
98	I thought this was old news, but Dow_Jones Newswire just published it: Barr	tom pope	-	6/16/2003
97	KOSP KOS Pharma receives approval for Niaspan in the UK (23.70) Co receives f	tom pope	-	6/13/2003
96	13:56 ET KOSP KOS Pharma reit Outperform at Ryan Beck; ta	IRWIN JAMES FRANKEL	-	6/2/2003
95	Briefing: 07:26 ET KOSP KOS Pharma downgraded at Deutsche, UBS (24.36) Deu	tom pope	-	6/2/2003
94	Briefing: 12:21 ET KOSP Short-Squeeze Alert -- KOS Pharma (24.15 +1.06) Is	tom pope	-	5/27/2003

Go to reply# or date (mm/dd/yy):